VentureMed Group Appoints Bruce Fiedler as Chief Financial Officer to Drive Growth and Innovation

VentureMed Group Welcomes Bruce Fiedler as New CFO

In a significant move aimed at bolstering its leadership team, VentureMed Group, Inc. has announced the appointment of Bruce Fiedler as the new Chief Financial Officer (CFO). This strategic decision comes as the company, a leading name in medical devices specializing in vascular preparation and access management technologies, aims to amplify its impact in the medical field.

Bruce Fiedler brings a wealth of experience to VentureMed, having held prominent positions within the healthcare and technology sectors. His previous role as Vice President of Finance and Global Controller at Boston Scientific, particularly in the Neuromodulation division, showcases his extensive background in overseeing financial strategies and frameworks for significant global business units. This experience will be invaluable as he takes charge of VentureMed's financial operations, strategic planning, financial reporting, capital allocation, and investor relations.

Denis Harrington, the CEO of VentureMed Group, expressed his enthusiasm for this appointment, stating, "We are excited to welcome Bruce to the VentureMed leadership team. His financial acumen and extensive experience in scaling operations within medical technology will be instrumental as we embark on our next phase of growth. Bruce's strategic leadership will further strengthen our financial foundation and position us for long-term value creation."

In his new role, Fiedler will be instrumental in supporting VentureMed Group's ongoing efforts to provide transformative vascular intervention solutions for both healthcare professionals and patients worldwide. His focus will align with the company’s mission to address unmet clinical needs through innovative vascular technologies.

Fiedler's career is characterized by a commitment to operational excellence, financial discipline, and cross-functional collaboration. These attributes have earned him a reputation for driving performance within complex, high-growth organizations. In his statement regarding his appointment, Fiedler expressed enthusiasm for joining VentureMed at a pivotal moment. He stated, "I am thrilled to be part of the organization during this crucial phase. The company's mission to tackle unmet clinical needs through innovative vascular solutions is urgent, and I look forward to working with the team to drive growth and deliver significant impact for both patients and physicians."

About VentureMed Group

VentureMed Group, Inc. is a pioneering medical device company headquartered in Minnesota, focused on developing endovascular solutions for arteriovenous (AV) access and treatments for peripheral vascular diseases. The company is widely recognized for its flagship device, the FLEX Vessel Prep™ system — a 510(k) FDA-approved and CE-marked technology designed to optimize vascular preparation through its proprietary Kinetic Endovascular Micro-Incision (KEMIC) technique. Unlike traditional balloon approaches that rely on static pressure, KEMIC utilizes controlled motion and dynamic vascular apposition to create precise and extended micro-incisions.

As VentureMed Group continues to innovate and expand its offerings, the addition of Bruce Fiedler to its leadership team marks a significant step forward in fulfilling its mission. For more information about VentureMed Group and its groundbreaking technologies, visit www.VentureMedgroup.com.